Nektar Therapeutics: Speeding Its Flight Towards the Moon
November 8, 2017
0
Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s fundamentals from reported finances, to reported products’ results, etc., Cash and investments in marketable securities at September 30, 2017, were $412.2 million as compared to $389.1 million at December 31, 2016. The cash includes the $150.0 million upfront payment by Eli Lilly & Company for the development and commercialization of NKTR-358. As Howard W. Robin, President and CEO of …